Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma

Wang,Zhi‑Peng; Chen,Shu‑Yuan; Tian,Ye

doi:10.3892/ol.2016.5475

Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma

Authors:
- Zhi‑Peng Wang
- Shu‑Yuan Chen
- Ye Tian
View Affiliations

Affiliations: Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: December 8, 2016 https://doi.org/10.3892/ol.2016.5475
Pages: 875-880

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wild-type p53-induced phosphatase (Wip1) is an established oncogene and is associated with development of multiple forms of human cancer. However, the expression and role of Wip1 in human bladder transitional cell carcinoma (TCC) remains to be elucidated. In the present study, immunohistochemistry demonstrated that Wip1 was overexpressed in bladder TCC tissues compared with corresponding normal bladder tissues in 106 bladder TCC cases (P<0.0001). Furthermore, high expression levels of Wip1 were significantly associated with increasing tumor size (P=0.002), pathological grade (P=0.025), clinical T stage (P=0.001) and lymph nodal metastasis (P=0.003). Kaplan‑Meier survival analysis identified that patients with high Wip1 expression levels exhibited a lower overall survival time (P<0.0001), and Cox proportional hazards regression model analysis demonstrated that Wip1 expression was an independent prognostic factor in patients with bladder TCC (P=0.025). In addition, downregulation of Wip1 expression by transfection with small interfering RNA in bladder cancer cells inhibited cell proliferation, invasion and migration (P<0.05), along with the upregulation of p53 protein levels (P<0.05). These findings suggest that Wip1 may function as a potential prognostic marker and therapeutic target in bladder cancer.

View Figures

View References

1	Burger M, Catto J, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S and Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
2	Boccardo F and Palmeri L: Adjuvant chemotherapy of bladder cancer. Ann Oncol. 17:(Suppl 5). v129–v132. 2006. View Article : Google Scholar : PubMed/NCBI
3	Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–301. 2016. View Article : Google Scholar : PubMed/NCBI
5	Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Woude GF Vande, O'Connor PM and Appella E: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA. 94:6048–6053. 1997. View Article : Google Scholar : PubMed/NCBI
6	Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, et al: Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet. 46:726–730. 2014. View Article : Google Scholar : PubMed/NCBI
7	Richter M, Dayaram T, Gilmartin AG, Ganji G, Pemmasani SK, Van Der Key H, Shohet JM, Donehower LA and Kumar R: Wip1 phosphatase as a potential therapeutic target in neuroblastoma. PLoS One. 10:e01156352015. View Article : Google Scholar : PubMed/NCBI
8	Sun GG, Zhang J, Ma XB, Wang YD, Chen YJ and Hu WN: Overexpression of wild-type p53-induced phosphatase1 confers poor prognosis of patients with nasopharyngeal carcinoma. Pathol Oncol Res. 21:283–291. 2015. View Article : Google Scholar : PubMed/NCBI
9	Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ and Liu J: Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma. PLoS One. 8:e607752013. View Article : Google Scholar : PubMed/NCBI
10	Sobin L, Gospodarowicz M and Wittekind C: TNM classification of malignant tumorsUICC International Union Against Cancer. 7th. Wiley-Blackwell; pp. 262–265. 2009
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A: European Association of Urology: EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the guidelines. Eur Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
13	Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, et al: Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell. 23:757–764. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lu X, Nannenga B and Donehower LA: PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19:1162–1174. 2005. View Article : Google Scholar : PubMed/NCBI
15	Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A and Minami Y: Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13:1170–1180. 2006. View Article : Google Scholar : PubMed/NCBI
16	Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M and Donehower LA: The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27:123–135. 2008. View Article : Google Scholar : PubMed/NCBI
17	Lowe J, Cha H, Lee MO, Mazur SJ, Appella E and Fornace AJ Jr: Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci (Landmark Ed). 17:1480–1498. 2012. View Article : Google Scholar : PubMed/NCBI
18	Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B, Hainaut P and Bourdon JC: Biological functions of p53 isoforms through evolution: Lessons from animal and cellular models. Cell Death Differ. 18:1815–1824. 2011. View Article : Google Scholar : PubMed/NCBI
19	Pfister C, Flaman JM, Dunet F, Grise P and Frebourg T: p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol. 162:69–73. 1999. View Article : Google Scholar : PubMed/NCBI
20	Crescenzi E, Raia Z, Pacifico F, Mellone S, Moscato F, Palumbo G and Leonardi A: Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells. J Biol Chem. 288:16212–16224. 2013. View Article : Google Scholar : PubMed/NCBI
21	Lu X, Ma O, Nguyen TA, Jones SN, Oren M and Donehower LA: The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell. 12:342–354. 2007. View Article : Google Scholar : PubMed/NCBI
22	Jiao L, Shen D, Liu G, Jia J, Geng J, Wang H and Sun Y: PPM1D as a novel biomarker for prostate cancer after radical prostatectomy. Anticancer Res. 34:2919–2925. 2014.PubMed/NCBI
23	Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J and Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patients survival. Cancer Sci. 102:1101–1106. 2011. View Article : Google Scholar : PubMed/NCBI
24	Sun GG, Wang YD, Liu Q and Hu WN: Expression of Wip1 in kidney carcinoma and its correlation with tumor metastasis and clinical significance. Pathol Oncol Res. 21:219–224. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wang HY, Liu ZS, Qiu L, Guo J, Li YF, Zhang J, Wang TJ and Liu XD: Knockdown of Wip1 enhances sensitivity to radiation in HeLa cells through activation of p38 MAPK. Oncol Res. 22:225–233. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ and Waldman FM: Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol. 26:970–978. 1995. View Article : Google Scholar : PubMed/NCBI